Holen Sie sich die Stockscreener-App
5.91
3.32%
0.19
Vorhandelsmarkt:
5.91
Schlusskurs vom Vortag:
$5.72
Offen:
$5.75
24-Stunden-Volumen:
59,976
Relative Volume:
0.45
Marktkapitalisierung:
$101.53M
Einnahmen:
$35.58M
Nettoeinkommen (Verlust:
$-17.89M
KGV:
-8.6619
EPS:
-0.6823
Netto-Cashflow:
$-17.74M
1W Leistung:
+1.55%
1M Leistung:
-3.27%
6M Leistung:
+44.15%
1J Leistung:
+19.78%
1-Tages-Spanne:
$5.645
$5.965
1-Wochen-Bereich:
$5.10
$6.00
52-Wochen-Spanne:
$3.28
$9.8212
Verrica Pharmaceuticals Inc Stock (VRCA) Company Profile
Firmenname
Verrica Pharmaceuticals Inc
Sektor
Branche
Telefon
484-453-3300
Adresse
10 NORTH HIGH STREET, WEST CHESTER, PA
Compare VRCA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VRCA
Verrica Pharmaceuticals Inc
|
5.91 | 98.26M | 35.58M | -17.89M | -17.74M | -0.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Verrica Pharmaceuticals Inc Stock (VRCA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-06 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-11-05 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-07-25 | Hochstufung | Needham | Hold → Buy |
| 2023-03-22 | Eingeleitet | Jefferies | Buy |
| 2023-02-13 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2022-05-25 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-05-14 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-12-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-06-30 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-24 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-24 | Eingeleitet | Needham | Buy |
| 2019-02-21 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Verrica Pharmaceuticals Inc Aktie (VRCA) Neueste Nachrichten
Verrica to Present Phase 2 Data on Skin Cancer Therapy at SID Meeting - MyChesCo
Block Trades: Is Verrica Pharmaceuticals Inc benefiting from innovation trendsM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Aug Rallies: Is Verrica Pharmaceuticals Inc stock good for income investors2026 Decliners & Low Risk Growth Stock Ideas - baoquankhu1.vn
Aug Big Picture: Will Verrica Pharmaceuticals Inc announce a stock split2026 Macro Impact & Consistent Profit Alerts - baoquankhu1.vn
Verrica Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
EPS Watch: Is Verrica Pharmaceuticals Inc stock a value trapWeekly Trend Report & Trade Opportunity Analysis - baoquankhu1.vn
Verrica Pharmaceuticals announces acceptance of late-breaking abstract highlighting potential abscopal effect of VP-315 for the treatment of basal cell carcinoma at the upcoming 2026 Society for Investigative Dermatology annual meeting - marketscreener.com
Skin cancer drug data from Verrica wins late-breaker slot in Chicago - Stock Titan
Chart Watch: Will Verrica Pharmaceuticals Inc announce a stock splitMarket Volume Report & Real-Time Sentiment Analysis - baoquankhu1.vn
Common Warts Treatment Market Outlook 2034: Insights on Clinical Trials, FDA/EMA/PMDA Approvals, NDA Progress, Therapeutics, Disease Prevalence, Mechanisms, Market Size, Key Companies | DelveInsight - Barchart.com
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference - marketscreener.com
Needham conference adds Verrica CEO; webcast runs live April 15 - Stock Titan
Published on: 2026-04-01 04:27:23 - baoquankhu1.vn
Market Trends: How does Verrica Pharmaceuticals Inc score in quality rankingsProfit Target & Safe Swing Trade Setups - baoquankhu1.vn
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Sees Large Growth in Short Interest - MarketBeat
Published on: 2026-03-31 18:08:06 - baoquankhu1.vn
Common Warts Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Verrica Pharma, Kino Pharma, Iwaki Pharma, Aclaris Therapeutics, KinoPharma - Barchart.com
Nasdaq Moves: How does Verrica Pharmaceuticals Inc perform in inflationary periodsDollar Strength & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Verrica Pharmaceuticals to Present at Jefferies Global Healthcare Conference - MSN
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Average Recommendation of "Hold" by Analysts - MarketBeat
Verrica Pharmaceuticals reports 2025 results and YCANTH sales growth - MSN
Dip Buying: Is Verrica Pharmaceuticals Inc a turnaround story2026 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Verrica Pharmaceuticals appoints Chris Chapman as chief commercial officer - MSN
VRCA Investors Have the Opportunity to Join Investigation of Verrica Pharmaceuticals Inc. with the Schall Law Firm - weeklyvoice.com
VRCA Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - weeklyvoice.com
Verrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - The Joplin Globe
FinancialContentVerrica Pharmaceuticals Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of Verrica Pharmaceuticals Inc. – VRCA - FinancialContent
Verrica Pharmaceuticals upgraded to buy from hold at Brookline - MSN
Verrica Pharmaceuticals schedules conference call to discuss 2025 results - MSN
Verrica Pharmaceuticals Reports 2025 Results and YCANTH Sales Growth - MyChesCo
Verrica Pharmaceuticals Q4 Loss Reignites Debate On Path To Sustainable Profitability - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Zevra Therapeutics (ZVRA), Verrica Pharmaceuticals (VRCA) and Beyond Air (XAIR) - The Globe and Mail
Verrica Pharmaceuticals Achieves 130% YCANTH Revenue Growth in 2025, Expands Global Pipeline, and Extends Cash Runway into 2027 - Minichart
Verrica Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Verrica Pharmaceuticals Gains CHMP Support for YCANTH® Marketing Application in Europe - MSN
Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlig - GuruFocus
Verrica Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Earnings call transcript: Verrica Pharmaceuticals Q4 2025 sees revenue surge - Investing.com Australia
YCANTH (VP-102): FDA-Approved Treatment for Molluscum Contagiosum and Dermatology Pipeline Overview | 2025 10-K Highlights - Minichart
VRCA: Revenue surged 368% in 2025, with strong YCANTH growth, cost cuts, and pipeline advances - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Announces Quarterly Earnings Results - MarketBeat
Verrica (VRCA) Achieves Strong Financial Milestones in 2025 - GuruFocus
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Verrica Pharmaceuticals 2025 10-K: $35.6M Revenue, $(1.68) EPS - TradingView
[10-K] Verrica Pharmaceuticals Inc. Files Annual Report | VRCA SEC FilingForm 10-K - Stock Titan
Verrica Pharmaceuticals Q4 revenue jumps on stronger YCANTH demand - TradingView
VRCA: Revenue up 370% in 2025, net loss narrowed, debt repaid, and YCANTH sales nearly doubled - TradingView
Verrica Pharmaceuticals (NASDAQ:VRCA) Downgraded by Zacks Research to Hold - MarketBeat
Verrica Pharmaceuticals Schedules Conference Call to Discuss 2025 Results - MyChesCo
Earnings Outlook For Verrica Pharmaceuticals - Benzinga
Finanzdaten der Verrica Pharmaceuticals Inc-Aktie (VRCA)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.69%
0.25%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):